Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map

The target’s significance, according to Recursion and its partners, rests in its potential to expand the universe of neuroscience treatments beyond the handful of familiar targets in the space. While more than three billion people are affected by neurological conditions worldwide, only one in 40 neuroscience drugs to ever reach the clinic have been approved.

The post Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map appeared first on GEN - Genetic Engineering and Biotechnology News.